Diagnostic accuracy of tumor M2-pyruvate kinase (tM2-PK) as a non-invasive biomarker in colorectal cancer: A systematic review and meta-analysis

IF 2.5 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY Clinical biochemistry Pub Date : 2023-10-01 DOI:10.1016/j.clinbiochem.2023.110652

Amir Hossein Aalami , Ali Shahriari , Mohammad Mazaheri , Farnoosh Aalami , Amir Amirabadi , Amirhossein Sahebkar

{"title":"Diagnostic accuracy of tumor M2-pyruvate kinase (tM2-PK) as a non-invasive biomarker in colorectal cancer: A systematic review and meta-analysis","authors":"Amir Hossein Aalami , Ali Shahriari , Mohammad Mazaheri , Farnoosh Aalami , Amir Amirabadi , Amirhossein Sahebkar","doi":"10.1016/j.clinbiochem.2023.110652","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><span><span>The tumor pyruvate kinase<span> M2 isoform (tM2-PK) is a glycolytic </span></span>enzyme isoform that is present on the surface of rapidly proliferating </span>cancer cells. The objective of this investigation was to assess the efficacy of the tM2-PK measurement assay in detecting colorectal cancer (CRC) through the analysis of serum/plasma and stool samples obtained from patients.</p></div><div><h3>Methods</h3><p><span>The pooled diagnostic performance measures, including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), the area under the curve (AUC), Q*index, and summary receiver-operating characteristic curve (SROC), were computed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. The statistical methods of I</span><sup>2</sup> and chi-square were employed to assess the presence of heterogeneity. The estimation of publication bias was conducted through the implementation of Begg's rank correlation and Egger's regression asymmetry tests.</p></div><div><h3>Results</h3><p>A total of 28 studies were found, involving 2900 participants (1560 cases and 1340 controls). The diagnostic accuracy of tM2-PK was calculated in CRC based on the pooled sensitivity of 83.70% (95% CI: 82.0% – 85.30%), specificity of 74.0% (95% CI: 72.0% – 76.0%), PLR of 4.432 (95% CI: 3.33 – 5.60), NLR of 0.187 (95% CI: 0.144 – 0.243), DOR of 30.182 (95% CI: 19.761 – 46.10) as well as AUC at 91.6%, and Q*-index at 85.0%. Publication bias was seen based on Begg's (<em>p</em> = 0.0006) and Egger's (<em>p</em> = 0.00015) tests.</p></div><div><h3>Conclusion</h3><p>The results demonstrate that tM2-PK exhibits promise as a fair marker for CTRC, with the potential to serve as a non-invasive biomarker.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912023001807","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The tumor pyruvate kinase M2 isoform (tM2-PK) is a glycolytic enzyme isoform that is present on the surface of rapidly proliferating cancer cells. The objective of this investigation was to assess the efficacy of the tM2-PK measurement assay in detecting colorectal cancer (CRC) through the analysis of serum/plasma and stool samples obtained from patients.

Methods

The pooled diagnostic performance measures, including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), the area under the curve (AUC), Q*index, and summary receiver-operating characteristic curve (SROC), were computed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. The statistical methods of I² and chi-square were employed to assess the presence of heterogeneity. The estimation of publication bias was conducted through the implementation of Begg's rank correlation and Egger's regression asymmetry tests.

Results

A total of 28 studies were found, involving 2900 participants (1560 cases and 1340 controls). The diagnostic accuracy of tM2-PK was calculated in CRC based on the pooled sensitivity of 83.70% (95% CI: 82.0% – 85.30%), specificity of 74.0% (95% CI: 72.0% – 76.0%), PLR of 4.432 (95% CI: 3.33 – 5.60), NLR of 0.187 (95% CI: 0.144 – 0.243), DOR of 30.182 (95% CI: 19.761 – 46.10) as well as AUC at 91.6%, and Q*-index at 85.0%. Publication bias was seen based on Begg's (p = 0.0006) and Egger's (p = 0.00015) tests.

Conclusion

The results demonstrate that tM2-PK exhibits promise as a fair marker for CTRC, with the potential to serve as a non-invasive biomarker.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤M2-丙酮酸激酶（tM2-PK）作为结直肠癌癌症非侵入性生物标志物的诊断准确性：系统综述和荟萃分析。

简介：肿瘤丙酮酸激酶M2亚型（tM2-PK）是一种糖酵解酶亚型，存在于快速增殖的癌症细胞表面。本研究的目的是通过分析从患者获得的血清/血浆和粪便样本，评估tM2-PK测量测定在检测结直肠癌癌症（CRC）中的功效。方法：使用Meta Disc V.1.4和Comprehensive Meta Analysis V.3.3软件计算合并诊断性能指标，包括敏感性、特异性、阳性似然比（PLR）、阴性似然比（NLR）、诊断优势比（DOR）、曲线下面积（AUC）、Q*指数和总结受试者工作特征曲线（SROC）。采用I2和卡方的统计方法来评估异质性的存在。发表偏倚的估计是通过Begg秩相关和Egger回归不对称检验进行的。结果：共发现28项研究，涉及2900名参与者（1560例病例和1340例对照）。tM2-PK在CRC中的诊断准确性是基于83.70%（95%CI:82.0%-85.30%）的合并敏感性、74.0%（95%CI:72.0%-76.0%）的特异性、4.432（95%CI:3.33-5.60）的PLR、0.187（95%CI:0.14%-0.243）的NLR、30.182（95%CI:19.761-46.10）的DOR以及91.6%的AUC来计算的，Q*-指数为85.0%。基于Begg’s（p=0.0006）和Egger’s（p=0.00015）检验发现发表偏倚。结论：结果表明，tM2-PK有望成为CTRC的一种公平标志物，有可能成为一种非侵入性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical biochemistry 医学-医学实验技术

CiteScore

5.10

自引率

0.00%

发文量

151

审稿时长

25 days

期刊介绍： Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.